Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions.
Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are categorized based on their microscopic appearance and cell characteristics. They are classified into various subtypes, and the World Health Organization (WHO) system categorizes them into different stages (from Type A to Type AB, B1, B2, B3, and thymic carcinoma).
The exact cause of thymoma is unknown. It is believed that genetic mutations or alterations in the cells of the thymus gland may contribute to the development of these tumors. Thymomas are sometimes associated with autoimmune disorders, such as myasthenia gravis, but the relationship between the two conditions is not fully understood. Thymomas often do not cause symptoms in the early stages. As the tumor grows, it may cause chest pain or pressure, coughing or difficulty breathing, shortness of breath, recurrent respiratory infections, or myasthenia gravis symptoms in some cases, including muscle weakness, drooping eyelids, and difficulty swallowing or speaking.
The Thymoma (Thymic Epithelial Tumor) drugs in development market research report provide comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thymoma (Thymic Epithelial Tumor) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thymoma (Thymic Epithelial Tumor) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 48 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thymoma (Thymic Epithelial Tumor) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thymoma (Thymic Epithelial Tumor) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thymoma (Thymic Epithelial Tumor) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acrotech Biopharma LLCAdlai Nortye Biopharma Co Ltd
Akeso Inc
Alphamab Oncology
Amgen Inc
Beijing Konruns Pharmaceutical Co Ltd
Betta Pharmaceuticals Co Ltd
Bristol-Myers Squibb Co
Chiome Bioscience Inc
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Hangzhou Gaotian Biological Medicine Co Ltd
Harpoon Therapeutics Inc
Ideaya Biosciences Inc
Ikena Oncology Inc
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Innate Pharma SA
Jiangsu Hengrui Medicine Co Ltd
Livzon Pharmaceutical Group Co Ltd
Merck & Co Inc
Merck KGaA
MiNK Therapeutics Inc
Novartis AG
Osaka University
Peking University
Pfizer Inc
Pharma Mar SA
Promontory Therapeutics Inc
Quadriga BioSciences Inc
SciClone Pharmaceuticals Holdings Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Biosciences Co Ltd
SOTIO Biotech AS
Starpharma Holdings Ltd
Stcube Inc
Syncromune Inc
Tiziana Life Sciences Plc
UTC Therapeutics Inc
VM Discovery Inc
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thymoma (Thymic Epithelial Tumor) reports